Longevity Health Financials
This page shows Longevity Health (XAGE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Longevity Health passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Longevity Health generates $0.42 in operating cash flow (-$4.4M OCF vs -$10.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Longevity Health earns $-169.8 in operating income for every $1 of interest expense (-$5.0M vs $29K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Longevity Health generated $50K in revenue in fiscal year 2024.
Longevity Health's EBITDA was -$4.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.9% from the prior year.
Longevity Health reported -$10.4M in net income in fiscal year 2024. This represents an increase of 32.9% from the prior year.
Longevity Health earned $-0.49 per diluted share (EPS) in fiscal year 2024. This represents an increase of 66.4% from the prior year.
Longevity Health held $157K in cash against $0 in long-term debt as of fiscal year 2024.
Longevity Health had 696,969 shares outstanding in fiscal year 2024. This represents a decrease of 97.0% from the prior year.
Longevity Health's gross margin was 87.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs.
Longevity Health's operating margin was -9933.8% in fiscal year 2024, reflecting core business profitability.
Longevity Health's net profit margin was -20605.5% in fiscal year 2024, showing the share of revenue converted to profit.
Longevity Health invested $1.1M in research and development in fiscal year 2024. This represents a decrease of 57.8% from the prior year.
XAGE Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $426K-15.4% | $504K-1.3% | $510K | N/A | $21K+66.6% | $12K | $0 | N/A |
| Cost of Revenue | $171K-14.7% | $201K-16.5% | $241K | N/A | $5K+1557.5% | $292 | $0 | N/A |
| Gross Profit | $254K-15.9% | $303K+12.2% | $270K | N/A | $16K+30.4% | $12K | $0 | N/A |
| R&D Expenses | $228K-12.3% | $260K+32.0% | $197K | N/A | $332K+218.8% | $104K-75.8% | $429K | N/A |
| SG&A Expenses | N/A | $1.4M | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -$1.5M+20.9% | -$1.9M-23.4% | -$1.5M | N/A | -$1.4M-19.2% | -$1.2M+13.7% | -$1.4M | N/A |
| Interest Expense | $5K+97.5% | $3K-48.7% | $5K | N/A | $7K+118.2% | $3K-71.8% | $12K | N/A |
| Income Tax | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Net Income | -$1.4M+24.2% | -$1.9M-25.3% | -$1.5M | N/A | -$2.9M+12.9% | -$3.3M-1.0% | -$3.3M | N/A |
| EPS (Diluted) | $-0.83+46.8% | $-1.56 | $-1.52 | N/A | $-4.13+13.6% | $-4.78-11.7% | $-4.28 | N/A |
XAGE Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.3M-11.3% | $3.7M+11.4% | $3.3M+126.4% | $1.5M-39.6% | $2.4M-51.5% | $5.0M-18.6% | $6.2M-90.3% | $63.9M |
| Current Assets | $2.8M-12.2% | $3.2M+16.0% | $2.8M+192.3% | $956K-49.3% | $1.9M-54.0% | $4.1M-21.0% | $5.2M-91.8% | $62.9M |
| Cash & Equivalents | $1.1M-28.5% | $1.6M+101.4% | $770K+390.0% | $157K-86.2% | $1.1M-48.3% | $2.2M+146.4% | $892K-69.4% | $2.9M |
| Inventory | $1.0M-13.6% | $1.2M-15.0% | $1.4M+1169.2% | $109K+11.0% | $98K-14.0% | $114K | N/A | $0 |
| Accounts Receivable | $47K-14.6% | $54K-42.5% | $95K+2213.3% | $4K | N/A | N/A | N/A | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.3M-2.4% | $7.5M+4.4% | $7.1M+15.5% | $6.2M-4.9% | $6.5M+1.6% | $6.4M-15.4% | $7.6M-80.7% | $39.2M |
| Current Liabilities | $6.8M-1.1% | $6.9M+4.8% | $6.6M+12.3% | $5.9M-4.8% | $6.2M+6.9% | $5.8M-16.3% | $6.9M-82.1% | $38.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$4.0M-6.4% | -$3.7M+1.8% | -$3.8M+19.3% | -$4.7M-15.9% | -$4.1M-196.3% | -$1.4M+1.4% | -$1.4M-105.6% | $24.7M |
| Retained Earnings | -$73.7M-2.0% | -$72.3M-2.7% | -$70.4M-2.2% | -$68.9M-1.3% | -$68.0M-4.4% | -$65.1M-5.3% | -$61.8M-5.6% | -$58.5M |
XAGE Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.4M-71.5% | -$836K-11.1% | -$753K+40.6% | -$1.3M-39.8% | -$907K+20.3% | -$1.1M-5.8% | -$1.1M+68.5% | -$3.4M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$3.4M |
| Investing Cash Flow | $776+105.2% | -$15K+90.0% | -$150K | $0 | $0 | $0+100.0% | -$749K | $0 |
| Financing Cash Flow | $991K-39.3% | $1.6M+7.7% | $1.5M+427.1% | $288K+286.7% | -$154K-106.3% | $2.4M+1349.0% | -$196K+74.7% | -$772K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
XAGE Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.8%-0.3pp | 60.1%+7.2pp | 52.9% | N/A | 76.4%-21.2pp | 97.6% | N/A | N/A |
| Operating Margin | -345.4%+23.6pp | -369.1%-73.8pp | -295.2% | N/A | -6919.4%+2751.8pp | -9671.2% | N/A | N/A |
| Net Margin | -335.7%+38.9pp | -374.6%-79.5pp | -295.1% | N/A | -14028.4%+12794.2pp | -26822.6% | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -43.3%+7.4pp | -50.7%-5.6pp | -45.1% | N/A | -117.9%-52.2pp | -65.6%-12.7pp | -52.9% | N/A |
| Current Ratio | 0.42-0.1 | 0.47+0.0 | 0.42+0.3 | 0.16-0.1 | 0.31-0.4 | 0.71-0.0 | 0.75-0.9 | 1.63 |
| Debt-to-Equity | -1.83+0.2 | -2.00-0.1 | -1.88-0.6 | -1.31+0.3 | -1.60+3.1 | -4.67+0.8 | -5.44-7.0 | 1.58 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$4.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.16), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Longevity Health's annual revenue?
Longevity Health (XAGE) reported $50K in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Longevity Health profitable?
No, Longevity Health (XAGE) reported a net income of -$10.4M in fiscal year 2024, with a net profit margin of -20605.5%.
What is Longevity Health's earnings per share (EPS)?
Longevity Health (XAGE) reported diluted earnings per share of $-0.49 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Longevity Health's EBITDA?
Longevity Health (XAGE) had EBITDA of -$4.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Longevity Health's gross margin?
Longevity Health (XAGE) had a gross margin of 87.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Longevity Health's operating margin?
Longevity Health (XAGE) had an operating margin of -9933.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Longevity Health's net profit margin?
Longevity Health (XAGE) had a net profit margin of -20605.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Longevity Health's operating cash flow?
Longevity Health (XAGE) generated -$4.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Longevity Health's total assets?
Longevity Health (XAGE) had $1.5M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Longevity Health spend on research and development?
Longevity Health (XAGE) invested $1.1M in research and development during fiscal year 2024.
How many shares does Longevity Health have outstanding?
Longevity Health (XAGE) had 696,969 shares outstanding as of fiscal year 2024.
What is Longevity Health's current ratio?
Longevity Health (XAGE) had a current ratio of 0.16 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Longevity Health's debt-to-equity ratio?
Longevity Health (XAGE) had a debt-to-equity ratio of -1.31 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Longevity Health's return on assets (ROA)?
Longevity Health (XAGE) had a return on assets of -703.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Longevity Health's cash runway?
Based on fiscal year 2024 data, Longevity Health (XAGE) had $157K in cash against an annual operating cash burn of $4.4M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Longevity Health's debt-to-equity ratio negative or unusual?
Longevity Health (XAGE) has negative shareholder equity of -$4.7M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Longevity Health's Piotroski F-Score?
Longevity Health (XAGE) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Longevity Health's earnings high quality?
Longevity Health (XAGE) has an earnings quality ratio of 0.42x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Longevity Health cover its interest payments?
Longevity Health (XAGE) has an interest coverage ratio of -169.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.